

**K250884 0.9 % Sodium Chloride Injection, USP, BD PosiFlush™  
SP Syringe**Dec 2, 2025  
253 days to decisionK250884 · Product code: **NGT** · General Hospital  
Source: <https://www.510kdatabase.net/k250884/>**SUBMISSION DETAILS**

---

Decision	Substantially Equivalent (Cleared)
Submission type	Traditional
Device classification	Saline, Vascular Access Flush (NGT)
Date received	Mar 24, 2025
Decision date	Dec 2, 2025
Days to decision	253 days
Third-party review	No
Combination product	No
PCCP authorized	No
Summary / Statement	Summary

**APPLICANT**

---

Company	<b>Becton, Dickinson and Company</b>
Location	Franklin Lakes, NJ, US
Contact	Michael Pacelli
Website	<a href="https://www.bd.com">https://www.bd.com</a>
510(k) history	134 submissions · 134 cleared · 2010-2026

Becton, Dickinson and Company is an American multinational medical technology company headquartered in Franklin Lakes, New Jersey. BD manufactures and sells medical devices, instrument systems, and reagents globally. The company maintains a strong FDA 510(k) regulatory record with FDA 510(k) clearances from total submissions spanning 2010 to 2026. BD's cleared devices span multiple categories including microbiology systems, blood collection products, and general hospital devices. The company's latest clearance in 2026 reflects continued innovation and regulatory engagement...